newsfilter
← Latest News
GlobeNewswire·

Zogenix Submits Supplemental New Drug Application for FINTEPLA® (Fenfluramine) for the Treatment of Seizures Associated with Lennox-Gastaut Syndrome

Supplemental New Drug Application (sNDA) submission is supported by existing clinical data, including positive data from Company's Phase 3 trial, Study 1601, in which the primary endpoint was met with high statistical significance. Lennox-Gastaut Syndr